These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18094402)

  • 41. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
    De Bock K; Cauwenberghs S; Carmeliet P
    Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth.
    Kangsamaksin T; Murtomaki A; Kofler NM; Cuervo H; Chaudhri RA; Tattersall IW; Rosenstiel PE; Shawber CJ; Kitajewski J
    Cancer Discov; 2015 Feb; 5(2):182-97. PubMed ID: 25387766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulatory T cells negatively regulate neovasculature of airway remodeling via DLL4-Notch signaling.
    Huang MT; Dai YS; Chou YB; Juan YH; Wang CC; Chiang BL
    J Immunol; 2009 Oct; 183(7):4745-54. PubMed ID: 19752226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiangiogenic agents and targets: A perspective.
    Teicher BA
    Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma.
    Haller BK; Bråve A; Wallgard E; Roswall P; Sunkari VG; Mattson U; Hallengärd D; Catrina SB; Hellström M; Pietras K
    Oncogene; 2010 Jul; 29(30):4276-86. PubMed ID: 20498640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of vascular morphogenesis by Notch signaling.
    Roca C; Adams RH
    Genes Dev; 2007 Oct; 21(20):2511-24. PubMed ID: 17938237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delta-like 4/Notch signaling promotes Apc
    Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
    BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delta-like ligand 4-notch blockade and tumor radiation response.
    Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
    J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Tumor angiogenesis].
    Bikfalvi A
    Bull Cancer; 2003 May; 90(5):449-58. PubMed ID: 12850768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth.
    Oon CE; Bridges E; Sheldon H; Sainson RCA; Jubb A; Turley H; Leek R; Buffa F; Harris AL; Li JL
    Oncotarget; 2017 Jun; 8(25):40115-40131. PubMed ID: 28445154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting tumor angiogenesis.
    Gaur P; Bose D; Samuel S; Ellis LM
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dll4-Notch signaling in regulation of tumor angiogenesis.
    Liu Z; Fan F; Wang A; Zheng S; Lu Y
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):525-36. PubMed ID: 24114288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?
    Griffioen AW
    Trends Cardiovasc Med; 2007 Jul; 17(5):171-6. PubMed ID: 17574125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
    Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
    Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of resistance to antiangiogenesis therapy.
    Azam F; Mehta S; Harris AL
    Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel therapeutic approaches for targeting tumor angiogenesis.
    Linkous AG; Yazlovitskaya EM
    Anticancer Res; 2012 Jan; 32(1):1-12. PubMed ID: 22213282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.